Description

BRAVECTO CHEWABLE 1400 MG

Indications

BRAVECTO Chewable 1400 mg is indicated for the treatment and prevention of flea infestations and for the treatment of tick infestations in dogs. It is effective against various species of ticks, including Ixodes ricinus (castor bean tick), Rhipicephalus sanguineus (brown dog tick), and Dermacentor variabilis (American dog tick). This product is designed for use in dogs weighing between 27.1 to 60 lbs (12.5 to 27 kg) and provides protection for up to 12 weeks with a single dose.

Mechanism of Action

BRAVECTO contains the active ingredient fluralaner, which belongs to the isoxazoline class of compounds. Fluralaner works by inhibiting the function of the insect neurotransmitter GABA (gamma-aminobutyric acid) and glutamate-gated chloride channels. This inhibition leads to the overstimulation of the nervous system in fleas and ticks, resulting in their death. The rapid onset of action allows for effective control of flea populations and a reduction in the risk of flea-borne diseases.

Pharmacological Properties

Fluralaner is absorbed quickly after oral administration, with peak plasma concentrations occurring within a few hours. The half-life of fluralaner in dogs is approximately 12 days, allowing for sustained efficacy against fleas and ticks over a prolonged period. The compound is primarily metabolized in the liver and excreted in urine and feces. BRAVECTO is known for its palatability, making it easy to administer to dogs, and it is safe for use in breeding, pregnant, and lactating dogs.

Contraindications

BRAVECTO should not be administered to dogs with a known hypersensitivity to fluralaner or any of the excipients in the formulation. Additionally, it is contraindicated in puppies less than 6 months of age or those weighing less than 12.5 kg (27.1 lbs). Caution should be exercised when administering BRAVECTO to dogs with a history of seizures or other neurological disorders, as the safety of fluralaner in such cases has not been fully established.

Side Effects

In clinical studies, BRAVECTO has been well tolerated by most dogs. However, some side effects may occur, including vomiting, diarrhea, decreased appetite, lethargy, and hypersalivation. These effects are generally mild and transient. In rare cases, more serious adverse reactions such as seizures or ataxia have been reported. Pet owners should monitor their dogs for any unusual behavior or signs of distress following administration of BRAVECTO and consult a veterinarian if concerns arise.

Dosage and Administration

BRAVECTO Chewable 1400 mg is administered as a single oral dose based on the dog’s weight. The recommended dosing schedule is every 12 weeks for optimal effectiveness. It can be given with or without food; however, administration with food may enhance absorption. It is essential to weigh the dog accurately before dosing to ensure proper administration. If a dose is missed, it should be given as soon as remembered, but not within the same 12-week period.

Interactions

Currently, there are no known significant drug interactions with BRAVECTO. However, it is advisable to inform the veterinarian of all medications, supplements, and treatments the dog is currently receiving prior to starting BRAVECTO. This includes any other flea or tick treatments, as concurrent use may lead to increased risk of adverse effects or diminished efficacy.

Precautions

While BRAVECTO is generally safe for use in most dogs, certain precautions should be taken. Dogs with a history of seizures or neurological disorders should be closely monitored. Additionally, it is important to ensure that the product is not used in conjunction with other isoxazoline-based products unless specifically directed by a veterinarian. Pet owners should also be aware of the potential for environmental reinfestation and should implement appropriate flea control measures in the home and yard.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of BRAVECTO in controlling flea and tick infestations in dogs. In a pivotal study, BRAVECTO was shown to eliminate fleas within 8 hours of administration and maintain efficacy against fleas for 12 weeks. The product also demonstrated a significant reduction in tick burdens, with efficacy lasting throughout the treatment period. The studies included a diverse population of dogs, ensuring that the results are applicable to a wide range of breeds and sizes.

Conclusion

BRAVECTO Chewable 1400 mg is a highly effective treatment for the prevention and control of flea and tick infestations in dogs. Its unique mechanism of action, combined with its long-lasting efficacy and palatability, makes it a preferred choice among pet owners and veterinarians. While generally safe, it is important to follow the recommended dosage and administration guidelines and to consult a veterinarian if any adverse effects or concerns arise. Regular use of BRAVECTO, along with proper environmental control measures, can help maintain a flea and tick-free environment for dogs and their families.